Get the Stockscreener App
12.33
7.30%
0.83
Emergent Biosolutions Inc stock is traded at $12.33, with a volume of 674.85K.
It is up +7.30% in the last 24 hours and down -3.67% over the past month.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
See More
Previous Close:
$11.50
Open:
$11.54
24h Volume:
674.85K
Relative Volume:
0.63
Market Cap:
$648.10M
Revenue:
$1.02B
Net Income/Loss:
$-757.20M
P/E Ratio:
-0.8354
EPS:
-14.76
Net Cash Flow:
$-257.90M
1W Performance:
+12.69%
1M Performance:
-3.67%
6M Performance:
+72.35%
1Y Performance:
+13.52%
1-Day Range:
$11.54
$12.58
1-Week Range:
$10.60
$12.58
52-Week Range:
$4.02
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Name
Emergent Biosolutions Inc
Sector
Phone
240-631-3200
Address
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
12.34 | 603.98M | 1.02B | -757.20M | -257.90M | -14.76 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-22-24 | Initiated | Rodman & Renshaw | Buy |
| Mar-07-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-20-23 | Resumed | JP Morgan | Underweight |
| Aug-29-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-10-23 | Upgrade | The Benchmark Company | Hold → Buy |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-10-22 | Downgrade | The Benchmark Company | Buy → Hold |
| Apr-29-22 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-20-22 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-08-21 | Downgrade | The Benchmark Company | Buy → Hold |
| May-05-21 | Downgrade | Argus | Buy → Hold |
| Apr-07-21 | Initiated | The Benchmark Company | Buy |
| Feb-24-21 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Feb-19-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-08-21 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-14-20 | Resumed | JP Morgan | Neutral |
| Jul-31-20 | Reiterated | Chardan Capital Markets | Buy |
| Sep-12-19 | Initiated | Guggenheim | Buy |
| Sep-04-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-02-18 | Upgrade | Goldman | Neutral → Buy |
| Aug-03-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-13-18 | Initiated | Argus | Buy |
| Apr-25-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jan-24-18 | Initiated | Goldman | Neutral |
| Jan-16-18 | Reiterated | Chardan Capital Markets | Buy |
| Jun-28-16 | Reiterated | Singular Research | Buy |
| Apr-15-16 | Initiated | Chardan Capital Markets | Buy |
| Mar-28-16 | Initiated | Singular Research | Buy |
| Feb-19-16 | Initiated | Wells Fargo | Outperform |
| May-15-14 | Initiated | Summer Street Research | Buy |
| May-31-11 | Reiterated | WBB Securities | Strong Buy |
| Jan-10-11 | Reiterated | Wedbush | Outperform |
| Nov-05-10 | Reiterated | Wedbush | Outperform |
| Aug-18-10 | Upgrade | WBB Securities | Buy → Strong Buy |
| Aug-06-10 | Reiterated | Caris & Company | Buy |
View All
Emergent Biosolutions Inc Stock (EBS) Latest News
Biotech Co. Gets OK For $10M Stalking Horse Bid - Law360
Emergent BioSolutions (EBS) receives a new order from US Department of War - MSN
Bispecific Antibody Market with Insights from Immunomedics, - openPR.com
Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing - FinancialContent
Former biotech CEO sued over COVID vaccine alleged insider trading - AOL.com
Moving Averages: Will Norfolk Southern Corporation outperform tech stocksJuly 2025 Catalysts & Safe Entry Trade Signal Reports - baoquankhu1.vn
Ex-Biotech CEO Cashed In $10M Ahead Of COVID Vaccine Crisis: Lawsuit - AOL.com
JPM movers: ImmunityBio rises to the top - BioCentury
FRAUD AND MANIPULATION—N.Y. Sup.: New York’s AG sues former Emergent BioSolutions CEO for insider trading - VitalLaw.com
Insider Sell: Can BOS Better Online Solutions Ltd disrupt its industryPortfolio Value Summary & AI Driven Price Forecasts - baoquankhu1.vn
Retail Trends: Is CMREPRC stock technically oversoldEarnings Trend Report & Daily Price Action Insights - baoquankhu1.vn
Lobbying Update: $430,000 of EMERGENT BIOSOLUTIONS INC lobbying was just disclosed - Quiver Quantitative
New York Sues Former C.E.O. of Covid Vaccine Maker Over Insider Trading - The New York Times
Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading - BioPharma Dive
Emergent BioSolutions (EBS) Receives a New Order from US Department of War - Insider Monkey
Emergent BioSolutions (EBS) Sued for Insider Trading, Agrees to $900K Settlement - Intellectia AI
Read This Before Judging Emergent BioSolutions Inc.'s (NYSE:EBS) ROE - Yahoo Finance
Emergent BioSolutions Inc. (EBS) Stock Analysis: Exploring a 23% Upside Potential and Robust Free Cash Flow - DirectorsTalk Interviews
Ex-CEO sued by New York for insider trading tied to COVID-19 vaccine contamination - 1470 & 100.3 WMBD
New Packaging Option for Narcan Nasal Spray Aims to Reduce Stigma - Psychiatry Advisor
Ex-CEO Of COVID Vax Maker Accused Of Insider Trading - Law360
Emergent Biosolutions Stock Plummets Amid Insider Trading Allegations Against Former CEO - Stocktwits
NY Attorney General Sues Former Emergent BioSolutions CEO for Insider Trading - The Wall Street Journal
Ex-CEO sued by New York for insider trading tied to COVID vaccine contamination - Reuters
NY Sues Ex-Emergent BioSolutions CEO for Insider Trading (1) - Bloomberg Law News
Emergent Biosolutions (NYSE:EBS) Stock Price Down 7.4%What's Next? - MarketBeat
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading -- Update - marketscreener.com
N.Y. Attorney General Sues Former Emergent Biosolutions CEO for Insider Trading - marketscreener.com
AstraZeneca (AZN) Involvement in Emergent's Legal Settlement - GuruFocus
Investors five-year losses continue as Emergent BioSolutions (NYSE:EBS) dips a further 7.5% this week, earnings continue to decline - Sahm
Emergent BioSolutions makes $100 million voluntary loan prepayment By Investing.com - Investing.com Nigeria
Emergent Biosolutions' Former CEO Sued for Insider Trading, Facing $900,000 Penalty - Intellectia AI
Emergent BioSolutions Inc CEO Presents at J.P. Morgan Healthcare Conference - TradingView — Track All Markets
Does Emergent BioSolutions (NYSE:EBS) Have A Healthy Balance Sheet? - 富途牛牛
Emergent BioSolutions Receives U.S. FDA Approval on Supplemental New Drug Application for NARCAN® Nasal Spray to be Packaged in a New Carrying Case, Making Life-Saving Naloxone More Accessible for Everyday Preparedness - The Manila Times
Emergent Biosolutions Receives U.S. FDA Approval On Supplemental New Drug Application For Narcan® Nasal Spray To Be Packaged In A New Carrying Case, Making Life-Saving Naloxone More Accessible For Everyday Preparedness - TradingView — Track All Markets
FDA clears discreet NARCAN case to help more people carry overdose spray - Stock Titan
Emergent BioSolutions, Inc. Announces Voluntary Prepayment of $100 Million Under its Outstanding Term Loan Facility - marketscreener.com
Emergent BioSolutions Announces $100 Million Loan Paydown - citybiz
Emergent BioSolutions makes $100 million voluntary loan prepayment - Investing.com
Emergent BioSolutions Inc Announces $100 Million Term Loan Prepayment - TradingView — Track All Markets
Emergent BioSolutions Announces $100 Million Paydown of Term Loan Principal, a Significant Step Achieved Toward its Multi-year Transformation - The Globe and Mail
Emergent BioSolutions announces $100 million paydown of term loan principal, a significant step achieved toward its multi-year transformation - marketscreener.com
Emergent Biosolutions Announces $100 Million Paydown Of Term Loan Principal, A Significant Step Achieved Toward Its Multi-Year Transformation - TradingView — Track All Markets
Emergent BioSolutions pays off $100M debt amid multi-year turnaround - Stock Titan
Market Review: Is Emergent BioSolutions Inc currently under institutional pressureJuly 2025 Short Interest & Weekly Momentum Stock Picks - baoquankhu1.vn
Published on: 2026-01-10 21:10:13 - Улправда
Will Emergent BioSolutions Inc. stock gain from government policiesJuly 2025 Trends & Accurate Entry and Exit Point Alerts - Улправда
Emergent BioSolutions (EBS) Secures $21.5M U.S. Defense Order fo - GuruFocus
Will Emergent BioSolutions Inc. stock maintain growth storyQuarterly Trade Summary & Community Driven Trade Alerts - Улправда
Emergent Biosolutions Inc Stock (EBS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):